A detailed history of Bell Investment Advisors, Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Bell Investment Advisors, Inc holds 19 shares of KRYS stock, worth $3,617. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19
Previous 13 46.15%
Holding current value
$3,617
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$174.7 - $213.66 $1,048 - $1,281
6 Added 46.15%
19 $3,000
Q2 2024

Aug 07, 2024

SELL
$153.12 - $183.64 $153 - $183
-1 Reduced 7.14%
13 $2,000
Q1 2024

May 08, 2024

BUY
$108.01 - $179.35 $1,512 - $2,510
14 New
14 $2,000
Q3 2023

Nov 08, 2023

BUY
$108.51 - $130.22 $434 - $520
4 New
4 $0
Q2 2022

Aug 12, 2022

SELL
$48.93 - $73.47 $440 - $661
-9 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$39.81 - $88.24 $358 - $794
9 New
9 $1,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Bell Investment Advisors, Inc Portfolio

Follow Bell Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bell Investment Advisors, Inc with notifications on news.